Quanome Technologies, Inc. (QNME): Entry into a Material Definitive Agreement
Quanome Technologies, Inc. (QNME) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 21, 2026, Quanome Technologies, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with Maxim Group LLC (the “Agent”), pursuant to which the Company may, from time to time, o
How this was made
The 30-second read
Why it matters
The ATM facility provides flexible financing up to $9.75 M, introducing dilution risk but also capital for potential acquisitions or development programs.
Market read
Primary disclosure of a capital‑raising mechanism for a micro‑cap biotech; may influence short‑term price action.
What to watch
The agreement includes a 3% transaction fee and a $40 k legal cost cap, which may reduce net proceeds and affect cash‑flow expectations.
Background
Quanome Technologies is a clinical‑stage biotech that filed a Form 8‑K to disclose a new ATM offering agreement with Maxim Group LLC.
Ticker impact
Quanome Technologies filed an 8‑K announcing an At‑The‑Market offering agreement to sell up to $9.75 M of common stock.
likely downward pressure as the market prices in possible dilution from the ATM offering
The company can now sell shares at any time, which typically depresses the stock until proceeds are used for growth.
Market effects
May signal increased financing activity in the biotech/clinical‑stage sector, prompting peers to consider similar capital structures.
Limited to U.S. small‑cap market; no broader regional effect.
Low; the filing is company‑specific and does not affect global markets.
Counterpoint
If the proceeds fund a high‑impact acquisition or breakthrough trial, the dilution could be offset by future upside.
Key entities
- companyQuanome Technologies, Inc.
Issuer of the ATM offering.
- agentMaxim Group LLC
Sales agent for the ATM offering.
